Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/140528
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hou, F. | - |
dc.contributor.author | Guo, Z. | - |
dc.contributor.author | Ho, M.T. | - |
dc.contributor.author | Hui, Y. | - |
dc.contributor.author | Zhao, C.-X. | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | ACS Nano, 2024; 18(12):8571-8599 | - |
dc.identifier.issn | 1936-0851 | - |
dc.identifier.issn | 1936-086X | - |
dc.identifier.uri | https://hdl.handle.net/2440/140528 | - |
dc.description.abstract | T cell-based adoptive cell therapy (ACT) has emerged as a promising treatment for various diseases, particularly cancers. Unlike other immunotherapy modalities, ACT involves directly transferring engineered T cells into patients to eradicate diseased cells; hence, it necessitates methods for effectively activating and expanding T cells in vitro. Artificial antigen-presenting cells (aAPCs) have been widely developed based on biomaterials, particularly micro- and nanoparticles, and functionalized with T cell stimulatory antibodies to closely mimic the natural T cell-APC interactions. Due to their vast clinical utility, aAPCs have been employed as an off-the-shelf technology for T cell activation in FDA-approved ACTs, and the development of aAPCs is constantly advancing with the emergence of aAPCs with more sophisticated designs and additional functionalities. Here, we review the recent advancements in particle-based aAPCs for T cell activation in ACTs. Following a brief introduction, we first describe the manufacturing processes of ACT products. Next, the design and synthetic strategies for micro- and nanoparticle-based aAPCs are discussed separately to emphasize their features, advantages, and limitations. Then, the impact of design parameters of aAPCs, such as size, shape, ligand density/mobility, and stiffness, on their functionality and biomedical performance is explored to provide deeper insights into the design concepts and principles for more efficient and safer aAPCs. The review concludes by discussing current challenges and proposing future perspectives for the development of more advanced aAPCs. | - |
dc.description.statementofresponsibility | Fei Hou, Zichao Guo, Minh Trang Ho, Yue Hui, and Chun-Xia Zhao | - |
dc.language.iso | en | - |
dc.publisher | American Chemical Society (ACS) | - |
dc.rights | © 2024 American Chemical Society | - |
dc.source.uri | http://dx.doi.org/10.1021/acsnano.3c10180 | - |
dc.subject | adoptive cell therapy | - |
dc.subject | artificial antigen-presenting-cell | - |
dc.subject | CAR-T therapy | - |
dc.subject | microparticle | - |
dc.subject | nanoparticle | - |
dc.subject | particle size | - |
dc.subject | stiffness | - |
dc.subject | T cell activation | - |
dc.subject | T cell expansion | - |
dc.subject.mesh | Antigen-Presenting Cells | - |
dc.subject.mesh | T-Lymphocytes | - |
dc.subject.mesh | Humans | - |
dc.subject.mesh | Immunotherapy | - |
dc.subject.mesh | Immunotherapy, Adoptive | - |
dc.subject.mesh | Lymphocyte Activation | - |
dc.subject.mesh | Cell- and Tissue-Based Therapy | - |
dc.title | Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1021/acsnano.3c10180 | - |
dc.relation.grant | http://purl.org/au-research/grants/arc/DP20129314 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/2026797 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/2008698 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Hou, F. [0000-0003-4043-6696] | - |
dc.identifier.orcid | Ho, M.T. [0000-0001-5250-6546] | - |
dc.identifier.orcid | Hui, Y. [0000-0002-1057-5671] | - |
Appears in Collections: | Research Outputs |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.